Lupin recalls diabetes treatment drug Metformin Hydrochloride in US


Drug major Lupin Ltd on Wednesday said it is voluntarily recalling its diabetes treatment drug Metformin Hydrochloride extended-release tablets in the US market.

In a regulatory filing, the company said that it is voluntarily recalling its Metformin Hydrochloride extended-release tablets USP, 500 mg and 1000 mg products in the US.

"This recall is being conducted out of an abundance of caution in line with the ongoing interaction with the US Food and Drug Administration on NDMA impurity levels," the filing said.

Lupin's US subsidiary, Lupin Pharmaceuticals Inc, distributes Metformin Hydrochloride extended-release tablets USP in the strengths of 500 mg and 1000 mg in the US.

"We believe that the issues identified in the concerned products are addressable and we expect to re-introduce our updated Metformin Hydrochloride extended-release tablet product(s) in the US during the current quarter," the company said.

Further, "we wish to separately clarify that all of the company's Metformin products manufactured and marketed in India have been tested for NDMA levels and have been assessed to be safe for patients and comply with all relevant regulatory norms," it said.

The company said the "aforementioned products are part of a completely separate supply chain with respect to their Active pharmaceutical ingredient (API) source, formulation process and manufacturing sites".

The impurity, N-Nitrosodimethylamine (NDMA), is classified as a probable human carcinogen based on results from laboratory tests. It is a known environmental contaminant and found in water and foods, including meats, dairy products and vegetables.

Metformin Hydrochloride extended-release tablets is a prescription oral medication indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type-2 diabetes mellitus.

Shares of Lupin were trading 0.64 per cent higher at Rs 876.35 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel